Becton Dickinson and Company (BDX)vsNephros Inc (NEPH)
BDX
Becton Dickinson and Company
$158.27
+1.51%
HEALTHCARE · Cap: $56.49B
NEPH
Nephros Inc
$3.05
-1.93%
HEALTHCARE · Cap: $33.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 116585% more annual revenue ($21.92B vs $18.79M). BDX leads profitability with a 8.0% profit margin vs 6.4%. BDX trades at a lower P/E of 25.5x. BDX earns a higher WallStSmart Score of 61/100 (C+).
BDX
Buy61
out of 100
Grade: C+
NEPH
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.9%
Fair Value
$286.42
Current Price
$158.27
$128.15 discount
Margin of Safety
-438.7%
Fair Value
$0.75
Current Price
$3.05
$2.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Earnings expanding 28.6% YoY
Revenue surging 22.2% year-over-year
Areas to Watch
Moderate valuation
1.6% revenue growth
ROE of 7.0% — below average capital efficiency
Distress zone — elevated risk
Moderate valuation
Smaller company, higher risk/reward
6.4% margin — thin
Operating margin of 0.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth. Revenue growth of 22.2% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : NEPH
The primary concerns for NEPH are P/E Ratio, Market Cap, Profit Margin.
Key Dynamics to Monitor
BDX profiles as a value stock while NEPH is a growth play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.48 — expect wider price swings.
NEPH is growing revenue faster at 22.2% — sustainability is the question.
BDX generates stronger free cash flow (549M), providing more financial flexibility.
Bottom Line
BDX scores higher overall (61/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?